A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC
Findings from the CheckMate 8HW study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1589 results
Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for Patients with Haematologic Malignancies
Findings from a randomised, controlled study
Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among Different Interventions Across the Cancer Control Continuum
Findings from a model-based study using population-level data
FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Evidence for efficacy is based on the results from the Study CK-301-101
EMA Recommends Extension of Indications for Blinatumomab
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor ALL
A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC
Findings from the SGNTUC-019 study
Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors
Findings from a translational analysis of the FOENIX study and a comprehensive analysis of primary data from a multi-institutional patient cohort with FGFR-altered cholangiocarcinoma
Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations
Findings from the TROPION-Lung05 study
FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC
Evidence for efficacy is based on the results from the BREAKWATER study
EMA Recommends Extension of Indications for Dostarlimab
Change concerns the first-line treatment of patients with endometrial cancer
Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment
Findings from the KATHERINE study
Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma
Findings from a substudy 02C of the KEYMAKER-U02 trial